指南与共识药物相互作用治疗药物监测与药物基因组学

生理药代动力学模型评估转运体介导的药物相互作用支持扎维吉泮鼻喷雾剂标签建议

Physiologically Based Pharmacokinetic Modeling to Assess Transporter-Mediated Drug-Drug Interactions in Support of Labeling Recommendations for Zavegepant Nasal Spray.
指南 / 共识 · Clin Pharmacol Ther · 2026-09-04

扎维吉泮鼻喷雾剂是OATP1B3、NTCP、P-gp和CYP3A4的底物。研究基于体外、人体质量平衡和临床药代动力学数据建立并验证PBPK模型,评估临床DDI机制并支持标签建议。模型预测单剂量利福平使鼻喷扎维吉泮AUC比值为2.39,多剂量利福平为2.11,环孢素A为1.58倍;CYP3A诱导剂影响极小;OATP1B3/NTCP抑制剂可显著增加暴露,应避免合用。

要点

  • CYP3A/P-gp抑制剂和诱导剂对鼻喷扎维吉泮暴露无临床相关影响。
  • OATP1B3/NTCP抑制剂可显著增加鼻喷扎维吉泮暴露,应避免合用。
  • PBPK模型预测单剂量利福平使鼻喷扎维吉泮AUC比值达2.39。

核心结论

  • PBPK建模和观察到的PK数据支持CYP3A/P-gp抑制剂和诱导剂不会对鼻喷扎维吉泮血浆暴露产生临床相关调节。
  • OATP1B3/NTCP抑制剂可显著增加鼻喷扎维吉泮暴露,应避免合用。

研究设计与样本

  • 基于体外、人体质量平衡和观察到的临床扎维吉泮药代动力学数据建立并验证PBPK模型,用于评估临床DDI机制并支持扎维吉泮鼻喷雾剂标签建议。

主要发现

  • PBPK建模表明,伊曲康唑与口服扎维吉泮之间的DDI主要由肠道P-gp抑制驱动,多剂量利福平的DDI主要源于肝脏摄取抑制。
  • 模型预测单剂量利福平使鼻喷扎维吉泮血浆暴露增加(AUCR=2.39),多剂量利福平也使鼻喷扎维吉泮血浆暴露增加(AUCR=2.11)。
  • 当假设OATP1B3:NTCP对肝脏摄取贡献比为90:10时,预测单剂量环孢素A使鼻喷扎维吉泮暴露变化为1.58倍(AUCR)。
  • 预测CYP3A诱导剂卡马西平和依非韦伦对鼻喷扎维吉泮PK影响极小。

关键数值与推荐

  • 单剂量利福平使鼻喷扎维吉泮AUCR=2.39。
  • 多剂量利福平使鼻喷扎维吉泮AUCR=2.11。
  • 单剂量环孢素A使鼻喷扎维吉泮AUCR=1.58(假设OATP1B3:NTCP贡献比为90:10)。
  • OATP1B3/NTCP抑制剂可显著增加鼻喷扎维吉泮暴露,应避免合用。

临床怎么用

  • 使用扎维吉泮鼻喷雾剂时应避免合用OATP1B3/NTCP抑制剂。
  • 与CYP3A/P-gp抑制剂或诱导剂合用时,预计无需调整扎维吉泮鼻喷雾剂剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Zavegepant nasal spray, a calcitonin gene-related peptide receptor antagonist indicated for acute treatment of migraine with or without aura in adults, is a substrate for organic anion transporting polypeptide 1B3 (OATP1B3), Na+/taurocholate cotransporting polypeptide (NTCP), P-glycoprotein (P-gp), and cytochrome P450 3A4 (CYP3A4). In clinical drug-drug interaction (DDI) studies, oral zavegepant exposure increased in the presence of multiple-dose (MD) rifampin or itraconazole; however, no interaction was observed between intranasal (IN) zavegepant and itraconazole. A physiologically based pharmacokinetic (PBPK) model was developed and validated using in vitro, human mass balance, and observed clinical zavegepant pharmacokinetic data and was employed to assess clinical DDI mechanisms and further support zavegepant nasal spray labeling recommendations. PBPK modeling indicated that DDI observed between itraconazole and oral zavegepant is primarily driven by intestinal P-gp inhibition, and observed DDI with MD rifampin primarily results from hepatic uptake inhibition. Modeling predicted an increase in plasma exposure (AUC ratio [AUCR] = 2.39) of IN zavegepant with single-dose (SD) rifampin; IN zavegepant plasma exposure was also predicted to increase with MD rifampin (AUCR = 2.11). Predicted IN zavegepant exposure change with SD cyclosporine A was 1.58-fold (AUCR) when assuming 90:10 proportion for OATP1B3:NTCP contribution to hepatic uptake. CYP3A inducers, carbamazepine and efavirenz, were predicted to have minimal effect on IN zavegepant PK. Overall, PBPK modeling and observed PK data support that CYP3A/P-gp inhibitors and inducers do not produce clinically relevant modulation in IN zavegepant plasma exposure; however, OATP1B3/NTCP inhibitors can significantly increase IN zavegepant exposure, and coadministration should be avoided.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ke A, Callegari E, Varma MVS, et al. Physiologically Based Pharmacokinetic Modeling to Assess Transporter-Mediated Drug-Drug Interactions in Support of Labeling Recommendations for Zavegepant Nasal Spray. Clin Pharmacol Ther. 2026. PMID: 42698006. doi:10.1002/cpt.70460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。